Abstract
Twenty five novel benzimidazole derivatives (1–25) evaluated for β-glucuronidase inhibitory activity. [Display omitted]
•Synthesis of 25 novel benzimidazole derivatives.•In vitro β-glucuronidase inhibitory activity.•Some of compounds are more active than standard drug.•Structure–activity relationship has been established.•Docking studies were carried out to confirm binding of active compounds with enzyme.
Twenty five 4, 6-dichlorobenzimidazole derivatives (1–25) have been synthesized and evaluated against β-glucuronidase inhibitory activity. The compounds which actively inhibit β-glucuronidase activity have IC50 values ranging between 4.48 and 46.12μM and showing better than standard d-saccharic acid 1,4 lactone (IC50=48.4±1.25μM). Molecular docking provided potential clues to identify interactions between the active molecules and the enzyme which further led us to identify plausible binding mode of all the benzimidazole derivatives. This study confirmed that presence of hydrophilic moieties is crucial to inhibit the human β-glucuronidase.